Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Does PAD and microcirculation status impact the tissue availability of intravenously administered antibiotics in patients with infected diabetic foot? Results of the DFIATIM substudy

V. Fejfarová, R. Jarošíková, S. Antalová, J. Husáková, V. Wosková, P. Beca, J. Mrázek, P. Tůma, J. Polák, M. Dubský, D. Sojáková, V. Lánská, M. Petrlík

. 2024 ; 15 (-) : 1326179. [pub] 20240507

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24013987

AIMS/HYPOTHESIS: The aim of this substudy (Eudra CT No:2019-001997-27)was to assess ATB availability in patients with infected diabetic foot ulcers(IDFUs)in the context of microcirculation and macrocirculation status. METHODS: For this substudy, we enrolled 23 patients with IDFU. Patients were treated with boluses of amoxicillin/clavulanic acid(AMC)(12patients) or ceftazidime(CTZ)(11patients). After induction of a steady ATB state, microdialysis was performed near the IDFU. Tissue fluid samples from the foot and blood samples from peripheral blood were taken within 6 hours. ATB potential efficacy was assessed by evaluating the maximum serum and tissue ATB concentrations(Cmax and Cmax-tissue)and the percentage of time the unbound drug tissue concentration exceeds the minimum inhibitory concentration (MIC)(≥100% tissue and ≥50%/60% tissue fT>MIC). Vascular status was assessed by triplex ultrasound, ankle-brachial and toe-brachial index tests, occlusive plethysmography comprising two arterial flow phases, and transcutaneous oxygen pressure(TcPO2). RESULTS: Following bolus administration, the Cmax of AMC was 91.8 ± 52.5 μgmL-1 and the Cmax-tissue of AMC was 7.25 ± 4.5 μgmL-1(P<0.001). The Cmax for CTZ was 186.8 ± 44.1 μgmL-1 and the Cmax-tissue of CTZ was 18.6 ± 7.4 μgmL-1(P<0.0001). Additionally, 67% of patients treated with AMC and 55% of those treated with CTZ achieved tissue fT>MIC levels exceeding 50% and 60%, respectively. We observed positive correlations between both Cmax-tissue and AUCtissue and arterial flow. Specifically, the correlation coefficient for the first phase was r=0.42; (P=0.045), and for the second phase, it was r=0.55(P=0.01)and r=0.5(P=0.021). CONCLUSIONS: Bactericidal activity proved satisfactory in only half to two-thirds of patients with IDFUs, an outcome that appears to correlate primarily with arterial flow.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24013987
003      
CZ-PrNML
005      
20240905134123.0
007      
ta
008      
240725e20240507sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fendo.2024.1326179 $2 doi
035    __
$a (PubMed)38774229
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Fejfarová, Vladimíra $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Czechia
245    10
$a Does PAD and microcirculation status impact the tissue availability of intravenously administered antibiotics in patients with infected diabetic foot? Results of the DFIATIM substudy / $c V. Fejfarová, R. Jarošíková, S. Antalová, J. Husáková, V. Wosková, P. Beca, J. Mrázek, P. Tůma, J. Polák, M. Dubský, D. Sojáková, V. Lánská, M. Petrlík
520    9_
$a AIMS/HYPOTHESIS: The aim of this substudy (Eudra CT No:2019-001997-27)was to assess ATB availability in patients with infected diabetic foot ulcers(IDFUs)in the context of microcirculation and macrocirculation status. METHODS: For this substudy, we enrolled 23 patients with IDFU. Patients were treated with boluses of amoxicillin/clavulanic acid(AMC)(12patients) or ceftazidime(CTZ)(11patients). After induction of a steady ATB state, microdialysis was performed near the IDFU. Tissue fluid samples from the foot and blood samples from peripheral blood were taken within 6 hours. ATB potential efficacy was assessed by evaluating the maximum serum and tissue ATB concentrations(Cmax and Cmax-tissue)and the percentage of time the unbound drug tissue concentration exceeds the minimum inhibitory concentration (MIC)(≥100% tissue and ≥50%/60% tissue fT>MIC). Vascular status was assessed by triplex ultrasound, ankle-brachial and toe-brachial index tests, occlusive plethysmography comprising two arterial flow phases, and transcutaneous oxygen pressure(TcPO2). RESULTS: Following bolus administration, the Cmax of AMC was 91.8 ± 52.5 μgmL-1 and the Cmax-tissue of AMC was 7.25 ± 4.5 μgmL-1(P<0.001). The Cmax for CTZ was 186.8 ± 44.1 μgmL-1 and the Cmax-tissue of CTZ was 18.6 ± 7.4 μgmL-1(P<0.0001). Additionally, 67% of patients treated with AMC and 55% of those treated with CTZ achieved tissue fT>MIC levels exceeding 50% and 60%, respectively. We observed positive correlations between both Cmax-tissue and AUCtissue and arterial flow. Specifically, the correlation coefficient for the first phase was r=0.42; (P=0.045), and for the second phase, it was r=0.55(P=0.01)and r=0.5(P=0.021). CONCLUSIONS: Bactericidal activity proved satisfactory in only half to two-thirds of patients with IDFUs, an outcome that appears to correlate primarily with arterial flow.
650    _2
$a lidé $7 D006801
650    12
$a diabetická noha $x farmakoterapie $x metabolismus $7 D017719
650    12
$a mikrocirkulace $x účinky léků $7 D008833
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a antibakteriální látky $x farmakokinetika $x aplikace a dávkování $x terapeutické užití $7 D000900
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a intravenózní podání $7 D061605
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jarošíková, Radka $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia $u Department of Internal Medicine, Second Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Antalová, Simona $u Department of Clinical Pharmacy and Drug Information Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Husáková, Jitka $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Wosková, Veronika $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Beca, Pavol $u Department of Clinical Pharmacy and Drug Information Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Mrázek, Jakub $u Laboratory of Anaerobic Microbiology, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Prague, Czechia
700    1_
$a Tůma, Petr $u Department of Hygiene, Third Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Polák, Jan $u Department of Pathophysiology, Third Faculty of Medicine, Charles University, Prague, Czechia
700    1_
$a Dubský, Michal $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Sojáková, Dominika $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Lánská, Věra $u Diabetes Centre, Institute for Clinical and Experimental Medicine, Prague, Czechia
700    1_
$a Petrlík, Martin $u Vascular and Internal Medicine Outpatient Clinic, Prague, Czechia
773    0_
$w MED00174543 $t Frontiers in endocrinology $x 1664-2392 $g Roč. 15 (20240507), s. 1326179
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38774229 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134117 $b ABA008
999    __
$a ok $b bmc $g 2143657 $s 1225853
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 15 $c - $d 1326179 $e 20240507 $i 1664-2392 $m Frontiers in endocrinology $n Front Endocrinol (Lausanne) $x MED00174543
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options